Provided By GlobeNewswire
Last update: May 12, 2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in four upcoming investor conferences. Details of the presentations are as follows:
Read more at globenewswire.comNASDAQ:BLTE (7/18/2025, 8:00:01 PM)
60.92
-0.07 (-0.11%)
Find more stocks in the Stock Screener